[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Richter et al., 2023 - Google Patents

Inhibition of muscarinic receptor signaling protects human enteric inhibitory neurons against platin chemotherapy toxicity

Richter et al., 2023

View PDF
Document ID
6448670501144453968
Author
Richter M
Farahvashi S
Samuel R
Majd H
Chemel A
Ramirez J
Majd A
Scantlen M
Elder N
Cesiulis A
Garcia K
Joshi T
Keefe M
Samiakalantari B
Turkalj E
Yu J
Arab A
Yin K
Culbertson B
Vora B
Xiong C
Kattah M
Irannejad R
Kroetz D
Nowakowski T
Goodarzi H
Fattahi F
Publication year
Publication venue
BioRxiv

External Links

Snippet

GI toxicity is a common dose-limiting adverse effect of platin chemotherapy treatment. Up to 50% of cancer survivors continue to experience symptoms of chronic constipation or diarrhea induced by their chemotherapy for many years after their treatment. This drug …
Continue reading at www.biorxiv.org (PDF) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Similar Documents

Publication Publication Date Title
Fortress et al. Canonical Wnt signaling is necessary for object recognition memory consolidation
Wang et al. Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells
Luo et al. Microarray analysis of selected genes in neural stem and progenitor cells
McEvoy et al. Coexpression of normally incompatible developmental pathways in retinoblastoma genesis
Jarazo et al. Parkinson's disease phenotypes in patient neuronal cultures and brain organoids improved by 2‐Hydroxypropyl‐β‐Cyclodextrin treatment
Pacheco-López et al. Neural substrates for behaviorally conditioned immunosuppression in the rat
Hwang et al. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation
Huang et al. Neuroprotective effects of reactive oxygen species mediated by BDNF-independent activation of TrkB
Upadhyay et al. Dysregulation of multiple signaling neurodevelopmental pathways during embryogenesis: a possible cause of autism spectrum disorder
Wegscheid et al. Patient-derived iPSC-cerebral organoid modeling of the 17q11. 2 microdeletion syndrome establishes CRLF3 as a critical regulator of neurogenesis
Shin et al. Sertindole, a potent antagonist at dopamine D2 receptors, induces autophagy by increasing reactive oxygen species in SH-SY5Y neuroblastoma cells
US20150025017A1 (en) Compositions and methods for treating cancer
Wu et al. Impairments of spatial learning and memory following intrahippocampal injection in rats of 3-mercaptopropionic acid-modified CdTe quantum dots and molecular mechanisms
Somerville et al. Mitochondria in the striatum of subjects with schizophrenia: relationship to treatment response
Lago et al. Drug discovery for psychiatric disorders using high-content single-cell screening of signaling network responses ex vivo
Richter et al. Inhibition of muscarinic receptor signaling protects human enteric inhibitory neurons against platin chemotherapy toxicity
Wen et al. Low concentration trifluoperazine promotes proliferation and reduces calcium-dependent apoptosis in glioma cells
Ivanova et al. Targeting FER kinase inhibits melanoma growth and metastasis
Xing et al. Fragile X mental retardation protein promotes astrocytoma proliferation via the MEK/ERK signaling pathway
Liu et al. Identification of PIK3CG as a hub in septic myocardial injury using network pharmacology and weighted gene co‐expression network analysis
de Bartolomeis et al. Canonical and non-canonical antipsychotics’ dopamine-related mechanisms of present and next generation molecules: a systematic review on translational highlights for treatment response and treatment-resistant schizophrenia
Russell et al. Exploring the potential of RET kinase inhibition for irritable bowel syndrome: a preclinical investigation in rodent models of colonic hypersensitivity
US20220087950A1 (en) Compounds, targets and pathways for macrophage modulation
Feng et al. A rat study model of depression‐driven chronic prostatitis by modulating the PI3K/Akt/mTOR network
Lee et al. High‐dose compound heat map for 3D‐cultured glioblastoma multiforme cells in a micropillar and microwell chip platform